Page 2 - Dcph News Today

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04, Briefing.com reports. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a […]

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the […]

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 […]

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price hoisted by equities research analysts at HC Wainwright from $25.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 152.95% […]

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) was upgraded by equities researchers at Jonestrading from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Benzinga reports. A number of other equities analysts have also issued reports on DCPH. Stifel Nicolaus upgraded shares of Deciphera Pharmaceuticals from a “hold” rating […]

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.03, MarketWatch Earnings reports. Deciphera Pharmaceuticals had a negative return on equity of 48.99% and a negative net margin of 127.92%. The firm […]

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price increased by Stifel Nicolaus from $20.00 to $22.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 88.68% from the company’s current price. DCPH has […]

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) CEO Steven L. Hoerter sold 21,573 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $12.02, for a total value of $259,307.46. Following the sale, the chief executive officer now owns 40,927 shares in the company, […]

DCPH | Complete Deciphera Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

By Dean Seal Deciphera Pharmaceuticals said the Phase 3 study of its treatment vimseltinib for tenosynovial giant cell tumors met its primary endpoint and...